Off-label use of medical products in radiation therapy
... are used in a manner not specified in the labeling, it is commonly referred to as off-label use. The practice of medicine allows for this off-label use to treat individual patients, but the ethical and legal implications for such unapproved use can be confusing. Although the responsibility and, ulti ...
... are used in a manner not specified in the labeling, it is commonly referred to as off-label use. The practice of medicine allows for this off-label use to treat individual patients, but the ethical and legal implications for such unapproved use can be confusing. Although the responsibility and, ulti ...
L. Araliaceae folium hederae helicis
... In erythematous conditions also T:a cinchonae 10-15 ml (decongestive esp. in lupus erythematosus). In psychoneurosis: 10 drp T. ad lib. Often. Ext. (se above): Unguentum 20% T. As compress./fomentat. 1 tsp T. on 10-15 ml wat. also as wash. The undiluted T. on insectsbites. Not more than recommended ...
... In erythematous conditions also T:a cinchonae 10-15 ml (decongestive esp. in lupus erythematosus). In psychoneurosis: 10 drp T. ad lib. Often. Ext. (se above): Unguentum 20% T. As compress./fomentat. 1 tsp T. on 10-15 ml wat. also as wash. The undiluted T. on insectsbites. Not more than recommended ...
Extrapyramidal motor side-effects of first
... such an analysis, we framed our results in the context of clinically important effects, defined as an odds ratio of 2.0 or 0.5, a double or half risk of EPS between the two study groups. Statistical power was limited but this approach allows us to conclude that there were few clinically relevant dif ...
... such an analysis, we framed our results in the context of clinically important effects, defined as an odds ratio of 2.0 or 0.5, a double or half risk of EPS between the two study groups. Statistical power was limited but this approach allows us to conclude that there were few clinically relevant dif ...
PHASE II DRUG METABOLISM: Glucuronidation and Sulfation
... mRNA supports diverse UGT2B isoform disposition in tissues. (Ohno S, Nakajin S, Drug Metab Dispos, 37: 32-40, 2009), though mRNA and protein expression are not always well correlated, especially when comparing isoforms. ...
... mRNA supports diverse UGT2B isoform disposition in tissues. (Ohno S, Nakajin S, Drug Metab Dispos, 37: 32-40, 2009), though mRNA and protein expression are not always well correlated, especially when comparing isoforms. ...
BIOGRAPHICAL SKETCH Leslie A. Kalish, ScD
... graft versus host disease (aGVHD) which is triggered by penetration of endotoxin from the intestines into the bloodstream. The protein rBPI21 is an endotoxin-neutralizing agent. This study will investigate the presence of endotoxin and how rBPI21 might alter the body’s inflammatory response to it. N ...
... graft versus host disease (aGVHD) which is triggered by penetration of endotoxin from the intestines into the bloodstream. The protein rBPI21 is an endotoxin-neutralizing agent. This study will investigate the presence of endotoxin and how rBPI21 might alter the body’s inflammatory response to it. N ...
GENERIC NAME: nefazodone
... peopke taking alprazolam who need to start taking nefazodone should have their alprazolam dose reduced by 50%. Nefazodone may increase the blood concentration of digoxin (Lanoxin), possibly leading to digoxin toxicity with side effects such as altered vision or nausea.nefazodone ...
... peopke taking alprazolam who need to start taking nefazodone should have their alprazolam dose reduced by 50%. Nefazodone may increase the blood concentration of digoxin (Lanoxin), possibly leading to digoxin toxicity with side effects such as altered vision or nausea.nefazodone ...
Parkinsonism
... Pyridoxine reversal of levodopa – do not occur On/Off effect – minimum Better overall improvement of patient ...
... Pyridoxine reversal of levodopa – do not occur On/Off effect – minimum Better overall improvement of patient ...
... to the L/T ratio, is to be expected when changing from one product to the other. Another approach is to produce an inhaler that delivers as much drug as possible to the lungs. The degrees of pulmonary bioavailability or (preferably) the pharmacodynamic responses for the old and new inhalers are dete ...
HIGHLIGHTS OF PRESCRIBING INFORMATION • appropriately. (5.5, 6.1)
... In addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro. In all clinical studies, severe central nervous system (CNS) hemorrhages, including fatalities, occurred in 1% of patients receiving SPRYCEL. Severe gastrointestinal hemorrhage, including fatal ...
... In addition to causing thrombocytopenia in human subjects, dasatinib caused platelet dysfunction in vitro. In all clinical studies, severe central nervous system (CNS) hemorrhages, including fatalities, occurred in 1% of patients receiving SPRYCEL. Severe gastrointestinal hemorrhage, including fatal ...
HIGHLIGHTS OF PRESCRIBING INFORMATION
... The dosage of PROTONIX I.V. for Injection in patients with pathological hypersecretory conditions including Zollinger-Ellison Syndrome varies with individual patients. The recommended adult dosage is 80 mg intravenously every 12 hours. The frequency of dosing can be adjusted to individual patient ne ...
... The dosage of PROTONIX I.V. for Injection in patients with pathological hypersecretory conditions including Zollinger-Ellison Syndrome varies with individual patients. The recommended adult dosage is 80 mg intravenously every 12 hours. The frequency of dosing can be adjusted to individual patient ne ...
RIXUBIS - Recombinant Coagulation Factor IX
... RIXUBIS contains trace amounts of hamster (CHO) proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins. Other factor IX products have had post-marketing reports of thrombotic events in patients receiving continuous-infusion through a central v ...
... RIXUBIS contains trace amounts of hamster (CHO) proteins. Patients treated with this product may develop hypersensitivity to these non-human mammalian proteins. Other factor IX products have had post-marketing reports of thrombotic events in patients receiving continuous-infusion through a central v ...
`False-positive` and `false-negative` test results in clinical urine drug
... Vapor Inhaler and generics), with which immunoassays for S(+)-methamphetamine may crossreact, yielding positive methamphetamine screening and confirmatory test results [13] . The potential for positive confirmatory test results due to R(-)-methamphetamine (also known as levomethamphetamine or desoxy ...
... Vapor Inhaler and generics), with which immunoassays for S(+)-methamphetamine may crossreact, yielding positive methamphetamine screening and confirmatory test results [13] . The potential for positive confirmatory test results due to R(-)-methamphetamine (also known as levomethamphetamine or desoxy ...
SUMMARY OF DATA FOR CHEMICAL SELECTION
... vincamine, is brought to the attention of the Chemical Selection Working Group. This problem first came to the attention of the National Cancer Institute’s (NCI) Division of Cancer Biology (DCB) when announcement of the availability of this new dietary supplement was made. Because the information su ...
... vincamine, is brought to the attention of the Chemical Selection Working Group. This problem first came to the attention of the National Cancer Institute’s (NCI) Division of Cancer Biology (DCB) when announcement of the availability of this new dietary supplement was made. Because the information su ...
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE
... The volume, strength and rate of infusion will depend upon the requirements of individual patients as perceived by the physician. Administration should be effected cautiously and gradually. In less urgent forms of metabolic acidosis, an average dose for adults and older children is 2-5 mmol of bicar ...
... The volume, strength and rate of infusion will depend upon the requirements of individual patients as perceived by the physician. Administration should be effected cautiously and gradually. In less urgent forms of metabolic acidosis, an average dose for adults and older children is 2-5 mmol of bicar ...
Volume 30 • Number 6 • 2013 - Controlled Release Society
... be heading in the next 10 years, and what will be the role of the CRS in supporting and encouraging these developments?” You might reasonably say that my crystal ball is as cloudy and fuzzy as any other CRS member’s, and you would be right—so here is my philosophy rather than my vision. To some degr ...
... be heading in the next 10 years, and what will be the role of the CRS in supporting and encouraging these developments?” You might reasonably say that my crystal ball is as cloudy and fuzzy as any other CRS member’s, and you would be right—so here is my philosophy rather than my vision. To some degr ...
Version 1
... CYP3A4 inducers, such as rifampicin, carbamazepin, phenytoin and St John´s Wort may induce the metabolism of oxycodone and cause an increased clearance of oxycodone that could cause a reduction of the plasma concentrations of oxycodone. The oxycodone dose may need to be adjusted accordingly. Some sp ...
... CYP3A4 inducers, such as rifampicin, carbamazepin, phenytoin and St John´s Wort may induce the metabolism of oxycodone and cause an increased clearance of oxycodone that could cause a reduction of the plasma concentrations of oxycodone. The oxycodone dose may need to be adjusted accordingly. Some sp ...
Enroflox Injection
... drug in food-producing animals. CONTRAINDICATIONS: Enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. The safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. The use of enrofloxacin is contraindicated in small and ...
... drug in food-producing animals. CONTRAINDICATIONS: Enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. The safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. The use of enrofloxacin is contraindicated in small and ...
procainamide hcl
... plasma concentration are compared , however , other have found that approximately 10 to 20 mg/L are required for partial suppression of ventricular concentration . Plasma concentration of NAPA of approximately equal to procainamide in many patients. Animal studies have been suggest that NAPA may be ...
... plasma concentration are compared , however , other have found that approximately 10 to 20 mg/L are required for partial suppression of ventricular concentration . Plasma concentration of NAPA of approximately equal to procainamide in many patients. Animal studies have been suggest that NAPA may be ...
Shionogi Presents New Clinical and Non-clinical Data on S
... This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertaint ...
... This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertaint ...
Temperature and pH Responsive Microfibers for Controllable and
... average release rate was only 0.09 µmol hr-1 at pH 7.4 and 40 oC. It is because pNIPAM-co-MAA became much more hydrophobic above its LCST, and thus functioned like a drug depot to prohibit the fast release of hydrophobic IP molecules. This rate was ~ 10 times slower than that at room temperatures. I ...
... average release rate was only 0.09 µmol hr-1 at pH 7.4 and 40 oC. It is because pNIPAM-co-MAA became much more hydrophobic above its LCST, and thus functioned like a drug depot to prohibit the fast release of hydrophobic IP molecules. This rate was ~ 10 times slower than that at room temperatures. I ...
Author`s personal copy - Texas Christian University
... [5,10]). The research reported here is concerned with the encoding of this aversive memory of the downshift. The effects of drugs on memory consolidation can be best assessed by posttrial drug administration, that is, by administering the drug immediately after the relevant experience. Memory consol ...
... [5,10]). The research reported here is concerned with the encoding of this aversive memory of the downshift. The effects of drugs on memory consolidation can be best assessed by posttrial drug administration, that is, by administering the drug immediately after the relevant experience. Memory consol ...
Determining Frequency of Prescription, Administration and
... observation method was used to detect errors. A pharmacy student observed 307 doses in 46 days of 6 h shifts. Observation data were entered in a form designed specifically for this purpose. Two hundred and fourteen MEs were identified in 307 doses. This is equivalent to 69.7% of total error. The err ...
... observation method was used to detect errors. A pharmacy student observed 307 doses in 46 days of 6 h shifts. Observation data were entered in a form designed specifically for this purpose. Two hundred and fourteen MEs were identified in 307 doses. This is equivalent to 69.7% of total error. The err ...
Efficacy and safety of a 12-week course of therapy with a new
... a new formulation of fluticasone at doses of 125 and 250 µg BID in comparison to the reference drug, fluticasone DPI 500 BID. We intended to demonstrate that the new formulation of the drug at the studied doses is as effective as the reference drug. The primary endpoint was a mean change in morning ...
... a new formulation of fluticasone at doses of 125 and 250 µg BID in comparison to the reference drug, fluticasone DPI 500 BID. We intended to demonstrate that the new formulation of the drug at the studied doses is as effective as the reference drug. The primary endpoint was a mean change in morning ...
ALTA Protocol - ARDS Network
... Study Design: Phase II/III prospective, randomized, double-blind, placebo controlled trial 1. Enrollment: approximately 36-48 months. 2. In Phase II, patients will be treated with aerosolized albuterol 5.0 mg (n=40-50) versus normal saline placebo (n= 40-50) administered every 4 hours for 10 days fo ...
... Study Design: Phase II/III prospective, randomized, double-blind, placebo controlled trial 1. Enrollment: approximately 36-48 months. 2. In Phase II, patients will be treated with aerosolized albuterol 5.0 mg (n=40-50) versus normal saline placebo (n= 40-50) administered every 4 hours for 10 days fo ...
The use of clozapine plasma levels in optimising therapy
... Centorrino et al (1995) found that there was no association between the degree of leucopenia caused by clozapine and clozapine or norclo zapine plasma levels. Clozapine serum levels are difficult to predict from the dose given and there are many factors which influence the serum level obtained. Shor ...
... Centorrino et al (1995) found that there was no association between the degree of leucopenia caused by clozapine and clozapine or norclo zapine plasma levels. Clozapine serum levels are difficult to predict from the dose given and there are many factors which influence the serum level obtained. Shor ...